Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H20N4O2.2H2O |
Molecular Weight | 336.3862 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.CCCC1C(=O)N2N(C1=O)C3=CC(C)=CC=C3N=C2N(C)C
InChI
InChIKey=LLMGYOJUHDRDFJ-UHFFFAOYSA-N
InChI=1S/C16H20N4O2.2H2O/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22;;/h7-9,11H,5-6H2,1-4H3;2*1H2
DescriptionSources: http://home.intekom.com/pharm/cont_eth/rheumox.htmlCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/770078
Sources: http://home.intekom.com/pharm/cont_eth/rheumox.html
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/770078
Azapropazone is a non-steroidal anti-inflammatory drug. It is indicated for use in the treatment of rheumatoid arthritis, osteo-arthritis and gout. Gastro-intestinal disturbances, allergic skin rashes and photosensitivity, headache, vertigo, oedema and kidney impairment may occur. Gastro-intestinal bleeding and angioedema have been reported. Pre-treatment with this drug failed to modify plasma concentrations of phenobarbitone. Brain levels of imipramine or desmethyl imipramine were unaffected 60 minutes after oral administration of imipramine.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/770078
Curator's Comment: Studies on the distribution of the drug revealed that low concentrations were measured in the brain.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: WP98 Sources: DOI: 10.1007/978-94-009-0713-3_4 |
3.0 µM [IC50] | ||
Target ID: GO:0030166 Sources: DOI: 10.1007/978-94-009-0713-3_4 |
|||
Target ID: GO:0032610 Sources: DOI: 10.1007/978-94-009-0713-3_4 |
|||
Target ID: CHEMBL1929 Sources: DOI: 10.1007/978-94-009-0713-3_4 |
15.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Rheumox Approved UseRheumox is usually prescribed for people with rheumatoid arthritis |
|||
Primary | Rheumox Approved UseIt is indicated for use in the treatment of osteo-arthritis |
|||
Primary | Rheumox Approved UseRheumox is usually prescribed for people with acute gouty inflammation of the joints. |
Sample Use Guides
In Vivo Use Guide
Sources: http://home.intekom.com/pharm/cont_eth/rheumox.html
The usual dose is 1200 mg per day, given as 600 mg twice daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2158370
Azapropazone is an inhibitor of a variety of neutrophil functions (migration, aggregation, superoxide production) at 40-400 ug/ml-1
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
90763
Created by
admin on Sat Dec 16 05:49:17 GMT 2023 , Edited by admin on Sat Dec 16 05:49:17 GMT 2023
|
PRIMARY | |||
|
m1983
Created by
admin on Sat Dec 16 05:49:17 GMT 2023 , Edited by admin on Sat Dec 16 05:49:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
22304-30-9
Created by
admin on Sat Dec 16 05:49:17 GMT 2023 , Edited by admin on Sat Dec 16 05:49:17 GMT 2023
|
PRIMARY | |||
|
DTXSID6022634
Created by
admin on Sat Dec 16 05:49:17 GMT 2023 , Edited by admin on Sat Dec 16 05:49:17 GMT 2023
|
PRIMARY | |||
|
SUB00638MIG
Created by
admin on Sat Dec 16 05:49:17 GMT 2023 , Edited by admin on Sat Dec 16 05:49:17 GMT 2023
|
PRIMARY | |||
|
BF18764H96
Created by
admin on Sat Dec 16 05:49:17 GMT 2023 , Edited by admin on Sat Dec 16 05:49:17 GMT 2023
|
PRIMARY | |||
|
100000085328
Created by
admin on Sat Dec 16 05:49:17 GMT 2023 , Edited by admin on Sat Dec 16 05:49:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD